Equities Analysts Offer Predictions for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Geron in a report issued on Thursday, November 7th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings of $0.01 per share for the quarter, down from their previous estimate of $0.02. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Geron's current full-year earnings is ($0.34) per share. Leerink Partnrs also issued estimates for Geron's Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.10 EPS and FY2026 earnings at $0.33 EPS.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.10% and a negative net margin of 682.48%. The firm had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. During the same period in the prior year, the company earned ($0.08) EPS. The firm's revenue was up 17138.4% compared to the same quarter last year.

A number of other equities research analysts have also issued reports on the stock. StockNews.com raised shares of Geron to a "sell" rating in a report on Monday, August 5th. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Geron in a report on Friday, August 9th. Leerink Partners began coverage on shares of Geron in a research report on Monday, September 9th. They set an "outperform" rating and a $7.00 price target for the company. HC Wainwright initiated coverage on shares of Geron in a research report on Tuesday, November 5th. They set a "buy" rating and a $8.00 price objective for the company. Finally, Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Geron in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Geron presently has a consensus rating of "Moderate Buy" and an average target price of $7.05.

Geron Trading Down 2.8 %

Shares of NASDAQ:GERN traded down $0.12 during midday trading on Monday, hitting $4.13. The company's stock had a trading volume of 3,534,627 shares, compared to its average volume of 10,430,890. The business's 50 day simple moving average is $4.31 and its 200 day simple moving average is $4.32. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61.

Institutional Trading of Geron

Large investors have recently made changes to their positions in the company. National Bank of Canada FI raised its stake in Geron by 1,200.0% in the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 6,000 shares in the last quarter. Crewe Advisors LLC grew its holdings in shares of Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC purchased a new stake in shares of Geron in the 1st quarter valued at about $34,000. American Trust purchased a new position in Geron during the 1st quarter worth approximately $38,000. Finally, Rovin Capital UT ADV acquired a new position in Geron during the third quarter worth approximately $62,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.